Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Infectious & Toxicology
Filter     Order     Display # 
Date Item Title
27 Oct 2008 Panacos Announces Preliminary Results of Bevirimat Study 204
24 Oct 2008 Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
24 Oct 2008 Astellas Announces the Withdrawal of EU MAA for Telavancin for Complicated Skin and Soft Tissue Infections
23 Oct 2008 Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
23 Oct 2008 Marketing Authorization Application for Lipsovir(R) submitted to European regulatory authorities.
22 Oct 2008 Targanta Therapeutics Releases Results from Phase 2 Simplifi Study Evaluating Single or Infrequent Doses of Oritavancin
22 Oct 2008 Sanofi-aventis and Medicines for Malaria Venture Enter Into Collaboration to Fight Malaria
22 Oct 2008 U.S. Food And Drug Administration (FDA) Approves PREZISTA® Once-Daily As Part Of Combination Therapy For Treatment-Naïve Adults With HIV-1
21 Oct 2008 CytoDyn Files New IND For Cytolin(R)
17 Oct 2008 Aeras and Crucell Announce TB Vaccine Clinical Trial in Kenya; Promising Vaccine Candidate Advances to Phase II Safety Study in South Africa
16 Oct 2008 Coarsucam (artesunate/amodiaquine) first fixed-dose antimalarial combination to receive WHO Prequalification
16 Oct 2008 Ranbaxy Achieves a Significant Landmark in Anti-Malarial Research
15 Oct 2008 Tibotec Begins Enrollment for Phase III Study of Telaprevir, an Investigational Agent, in HCV Patients Who Failed Prior Treatment
08 Oct 2008 Cenomed and TorreyPines Therapeutics Enter into Licensing Agreement
08 Oct 2008 Panacos' Study 114 Supports the Company's New Tablet Formulation of Bevirimat
07 Oct 2008 Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
02 Oct 2008 Progenics Announces Progress and Presentations in HIV Therapy Program
02 Oct 2008 Crucell Announces Positive Results of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US
02 Oct 2008 U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients
02 Oct 2008 Methylgene Receives Clinical Trial Approval from Health Canada for its Proprietary Product Candidate MGCD290 for Fungal Infections
01 Oct 2008 Advanced Life Sciences Announces NDA Submission for Cethromycin in Community Acquired Pneumonia
01 Oct 2008 Medivir: New Drug Application (NDA) for Lipsovir(R) Submitted to US FDA
30 Sep 2008 VaxInnate's Second Flu Vaccine Candidate Enters Clinical Development; Results Expected in Early 2009
29 Sep 2008 MedImmune Licenses Reverse Genetics Technology to Japan's BIKEN for Use in Influenza Vaccine Development and Production
25 Sep 2008 Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceed Expectations
24 Sep 2008 PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
24 Sep 2008 Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
24 Sep 2008 Critical Outcome Technologies Inc. to Advance HIV-1 Integrase Inhibitor Program with a Major Pharmaceutical Company
23 Sep 2008 Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins
22 Sep 2008 Trius Doses First Patient in Antibacterial Phase 2 Trial
21 Sep 2008 iBioPharma, Inc. Selects Influenza Vaccine as Its First Clinical Candidate
21 Sep 2008 Novartis MF59(R)-adjuvanted vaccine rapidly induces protective antibody levels against diverse strains of avian flu
21 Sep 2008 Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
18 Sep 2008 Three Rivers Pharmaceuticals(R), LLC Obtains Additional Commercial Rights to Infergen(R) from Amgen Inc.
17 Sep 2008 Myriad Genetics Announces Topline Results of Phase 1 Trial of Vivecon for HIV
17 Sep 2008 Gilead Receives Complete Response Letter from U.S. Food and Drug Administration for Aztreonam Lysine for Inhalation, an Investigational Treatment for Cystic Fibrosis
16 Sep 2008 Novartis receives FDA priority review for Coartem(R), potentially the first artemisinin-based combination treatment (ACT) for malaria in the US
15 Sep 2008 Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic with Activity Against Hospital- and Community-Acquired MRSA
12 Sep 2008 Clinical Trial Starts for Korea’s First Locally Developed Influenza Vaccine
10 Sep 2008 Cell Medica announces treatment of first patient in late stage clinical trial of adoptive cell therapy
10 Sep 2008 New Phase II data show Novartis investigational Meningitis B vaccine may also protect infants six months and older
10 Sep 2008 XOMA Awarded $65 Million Biodefense Contract by NIAID to Advance Drug Candidates Against Botulism Toxins Into Clinical Trials
10 Sep 2008 Altor BioScience Licenses T-cell Receptors Targeting HIV and Hepatitis C from Massachusetts General Hospital
09 Sep 2008 Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial
09 Sep 2008 Cubist Pharmaceuticals Provides Update on Advancing Product Pipeline
09 Sep 2008 Epiphany Biosciences to continue Phase 2 shingles study after interim analysis; plans follow-on clinical trial studying post-herpetic neuralgia (PHN)
08 Sep 2008 Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2
04 Sep 2008 Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
04 Sep 2008 Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
03 Sep 2008 Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 51 - 100 of 1267

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics